Article Details

Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US

Retrieved on: 2022-11-24 13:31:57

Tags for this article:

Click the tags to see associated articles and topics

Aurobindo unit, Evive Biotech ink licensing pact to commercialise CIN treatment product in US. View article details on hiswai:

Excerpt

The licensing pact has been inked between Evive and Acrotech Biopharma (Acrotech), a New Jersey-based and wholly-owned subsidiary of Aurobindo Pharma ...

Article found on: www.expresspharma.in

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up